| Mar 20 |
Does Castle Bioscience (CSTL) Have Robust Growth Prospects?
|
| Mar 19 |
Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy
|
| Mar 15 |
New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older
|
| Mar 12 |
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
|
| Mar 8 |
Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting
|
| Mar 7 |
In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups
|
| Mar 2 |
Castle Biosciences, Inc. (NASDAQ:CSTL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
|
| Mar 1 |
Castle Biosciences Full Year 2023 Earnings: Beats Expectations
|
| Mar 1 |
Castle Biosciences, Inc. (NASDAQ:CSTL): Are Analysts Optimistic?
|
| Feb 29 |
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
|
